XBB.1.5: What we know to date on this currently dominant viral subvariant


By AGENCY

Research suggests that the bivalent Covid-19 vaccines are more effective in producing an antibody response to XBB.1.5, compared to the earlier vaccines. — AFP

The Omicron viral subvariant XBB.1.5 is the most transmissible of the SARS-CoV-2 subvariants to emerge so far, and has been spreading quickly across the United States.

Here’s what we know – and don’t – about XBB.1.5.

Where and what

The subvariant was first detected in the US in October (2022), and now represents more than 27% of the country’s infections, according to the US Centres for Disease Control and Prevention’s variant tracker.

Thirty-eight countries have reported XBB.1.5 cases, of which 82% are in the US, 8% in the United Kingdom and 2% in Denmark, the World Health Organization (WHO) said in a rapid risk assessment on Jan 11 (2023).

The European Centre for Disease Prevention and Control (ECDC) said a week earlier that XBB.1.5 accounted for less than 2.5% of cases in Europe.

The subvariant is very similar to its predecessor XBB.1, but has an additional mutation to its spike protein – the key that allows the virus into the body’s cells – said Leeds University virologist Dr Grace Roberts.

Contagiousness and severity

Dr Maria Van Kerkhove, the WHO’s technical lead on Covid-19, said in early January (2023) that XBB.1.5 was the most transmissible form of Covid-19 and clearly has a “growth advantage” over other forms of the virus.

The most likely explanation for this advantage is the XBB.1.5’s spike protein mutation, in combination with the already very transmissible XBB, said the ECDC.

XBB.1.5 has a growth advantage over other Omicron viral variants of 109% in North America and 113% in Europe, the European Union health agency added, though it cautioned that these figures came with “significant uncertainty”.

It added that the proportion of XBB.1.5 cases had doubled every nine days in the US.

But Dr Roberts said that “there’s no data to suggest XBB.1.5 is any more harmful in terms of severe disease and death than previous variants”.

The WHO is still assessing data on the subject, but said XBB.1.5 did not carry any mutations that were known to increase severity.

Resistance to antibodies

Omicron’s XBB variants, alongside BQ.1, are the most resistant to antibodies built up from vaccination and previous infections, according to the WHO.

A study published in the journal Cell last month (December 2022) found that XBB.1 is 63 times less likely to be neutralised by existing antibodies than the BA.2 subvariant.

It is also 49 times more resistant than the BA.4 and BA.5 subvariants, which are currently dominant in the UK and numerous other countries.

Dr Roberts pointed to a recent preprint study, which has not been peer-reviewed, that suggests XBB.1.5 has a similar antibody resistance to XBB.1, but is more transmissible.

But it is “important to remember that antibodies are only one part of our immune systems,” she added.

US expert Dr Eric Topol said new research suggested that bivalent Covid-19 vaccines that target the BA.5 subvariant were also more effective in neutralising antibody response to XBB.1.5 than previous jabs.

That is because “the spike protein of the BA.5 bivalent more closely resembles XBB.1.5 than the Wuhan ancestral spike,” he wrote on Substack on Jan 13 (2023).

How concerning?

Dr Roberts said there was “no cause to panic” about XBB.1.5.

“I don’t think we need to take any drastic action at present,” she said, adding that it remains important for countries to monitor the subvariant’s progress.

The ECDC said the rapid growth of XBB.1.5 in the US did not necessarily mean it would become dominant in Europe because of “major differences in variant circulation” between the two regions throughout the pandemic.

Dr Topol said it was “good news” that hospital admissions among the elderly had mostly started to decline in the American northeast, where XBB.1.5 now accounts for more than 70% of cases.

The number of total Covid-19 cases worldwide dropped by 9% the first week of the month (January 2023), compared to the previous seven days, while deaths fell by 12%, according to the WHO, following a surge over the year-end holiday period.

The ‘Kraken’

The WHO has decided not to name Omicron subvariants after letters of the Greek alphabet.

But people on Twitter have been unofficially giving the various subvariants nicknames based on mythology, with XBB.1.5 dubbed the “Kraken”, Dr Roberts said.

“I personally think this may cause unnecessary concern, especially naming viruses after mythical giant sea creatures!” she added. – AFP Relaxnews

Article type: free
User access status:
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!
   

Next In Health

Covid-19 still an emergency, says WHO
Leprosy is no longer a major threat, but it's still being transmitted
Why mental health problems worsen in January
Germans to do pig-to-human heart transplants in two years
Eating less is more effective for losing weight than intermittent fasting
Cord blood stem cell transplant can save many lives
You can be young and still get a stroke
Want to remain fertile? Then change your lifestyle
Control your weight from young to avoid knee surgery when old
I'm pregnant and I just can't stop vomiting

Others Also Read